CAR-T Toxicology Service
Creative Biolabs provides a robust de-risking framework that translates complex biological responses into actionable regulatory data. We assist your project by identifying the "minimum anticipated biological effect level" (MABEL) and establishing safe starting doses, ensuring your application meets stringent international requirements. Our team specifically addresses the efficacy-toxicity balance, helping you understand if your construct's potency is inextricably linked to adverse events. By leveraging our state-of-the-art analytical platforms, we ensure that every potential safety concern, from on-target, off-tumor reactivity to long-term tumorigenicity, is addressed with scientific rigor.
Strategic Background: The Necessity of CAR-T Toxicology
The emergence of chimeric antigen receptor (CAR) T-cell therapy has fundamentally transformed the treatment of hematological malignancies, yet the unique "living" nature of these therapeutics introduces unprecedented safety risks. Unlike traditional small molecules, CAR-T cells undergo massive in vivo expansion and persistence, which can lead to life-threatening complications such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Robust preclinical toxicology is the indispensable bridge for identifying these risks before they manifest in biological systems. Current scientific consensus emphasizes that safety assessments must be dynamic, focusing on the complex interplay between CAR construct design and the systemic inflammatory cascades triggered upon antigen encounter.
Comprehensive Preclinical Evaluation
To ensure the highest safety standards for your chimeric antigen receptor therapies, Creative Biolabs offers an end-to-end toxicological evaluation suite. Our offerings are designed to probe the limits of your "living drug" in environments that mirror human physiology.
Customized In Vivo Toxicity Models
We offer a variety of rodent and non-rodent models, including specialized NCG/NOG humanized mice. These models allow for the evaluation of CAR-T cell expansion, persistence, and systemic inflammatory responses in a human-like immune environment.
Multiplex Cytokine Release Profiling
Utilizing high-sensitivity platforms, we offer real-time monitoring of critical biomarkers such as IL-6, IFN-γ, TNF-α, and IL-2. This data is essential for predicting the onset and severity of CRS.
Neurotoxicity & ICANS Assessment Platforms
Our specialized ICANS module evaluates blood-brain barrier (BBB) integrity and neuro-inflammation. We offer cognitive and motor impairment scoring (ICE scoring) to detect subtle neurological changes that standard toxicology screens often miss.
Cardiovascular Safety Monitoring
We provide comprehensive cardio-toxicology assessments, including serial ECG monitoring and high-sensitivity troponin/NT-proBNP biomarker analysis to identify CAR-T induced myocardial strain or arrhythmias.
Off-Target Specificity Screening
Through our advanced membrane protein arrays (MPA), we scan your CAR construct against over 6,000 human membrane proteins to identify potential "off-tumor" reactivities before they reach late-stage development.
Tumorigenicity & Genomic Stability Testing
We offer long-term monitoring services to assess the risk of insertional mutagenesis or malignant transformation of the transduced T-cells, ensuring long-term safety.
Don't leave your safety profile to chance—Request a Consultation with Our Safety Experts to De-risk Your Program
Workflow
Our workflow is designed to bridge the gap between initial construct design and regulatory submission, providing a clear roadmap for characterizing both acute and chronic safety profiles.
Publication
This review examines the toxicities associated with CAR-T cell therapy, including CRS, ICANS, tumor lysis syndrome (TLS), and on-target/off-tumor toxicity (OTOT). It summarizes their underlying mechanisms, clinical manifestations, and consensus grading, while emphasizing prevention and management strategies to balance therapeutic efficacy against potentially life-threatening adverse effects.
Fig.1 CAR-T cell therapy: mechanism of action and side effects. 1
Why Choose Us
Choosing Creative Biolabs means gaining access to a world-class infrastructure dedicated to the unique complexities of engineered cell therapies. Our primary advantage lies in our proprietary humanized NCG/NOG mouse models, which provide a significantly more accurate recapitulation of human cytokine release syndromes and expansion kinetics compared to standard rodent strains. Our cross-functional teams of immunologists and toxicologists ensure that your data is not merely a collection of numbers, but a strategic de-risking asset that optimizes trial design, refines patient selection criteria, and minimizes the potential for unexpected safety signals during late-stage development.
Leverage industry-leading expertise for your next breakthrough—Secure Your Competitive Project Quote Now
FAQs
How do you model CRS in animals if they don't respond like humans?
We utilize advanced humanized mouse models (e.g., NCG mice engrafted with human PBMCs), which allow for the measurement of human IL-6 and IFN-γ levels.
Can you evaluate the safety of "switchable" or "inducible" CARs?
Yes, our platform is designed to test the kinetics of "kill switches" (iCasp9) and adapter-mediated CARs to ensure rapid ablation of toxicity.
How do you handle the high costs of humanized models?
We offer tiered pricing and "pilot-to-pivot" study designs to ensure you only move to expensive models once initial safety signals are validated.
Customer Review
-
Exceptional Neuro-Assessment
Using Creative Biolabs' CAR-T toxicology in our research has significantly facilitated our understanding of BBB permeability issues. Their use of the ICE scoring system provided far more clarity than standard behavioral tests, allowing us to modify our hinge region for improved safety. - Dr. Aris***n T -
Reliable Cytokine Profiling
Using Creative Biolabs' CAR-T toxicology in our research has significantly improved our ability to predict the CRS onset window for our CD28-based CAR-T with incredible accuracy compared to our previous benchmarks. - Sarah M***z
Related Services
scFv Generation and Optimization
Creative Biolabs generates high-affinity scFvs via hybridoma and phage display. We provide humanization, affinity maturation, and ligand-based design to maximize CAR-T/NK/MA potency and safety while minimizing immunogenicity.
Learn More →Size Variants Analysis
Creative Biolabs uses optimized SEC methods to monitor scFv impurities like aggregates and dimers. We ensure stability and potency by detecting misfolded variants caused by incomplete or intermolecular disulfide bonding.
Learn More →Contact Us
Creative Biolabs provides the most comprehensive safety assessment for CAR-T therapies, ensuring that your innovative constructs are both potent and predictable. From early-stage specificity screening to full IND-enabling GLP studies, we are your partner in therapeutic success.
Ready to advance your therapy to the next stage? Contact Our Scientific Team Today for More Information and to Discuss Your Project Needs
Reference
- Zhang, Yugu, et al. "Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies." Journal of Clinical Medicine 12.19 (2023): 6124. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/jcm12196124
Download our brochure